ELEVATING EXPECTATIONS
IN PET CARE
PetMedix is delivering the next generation of proven monoclonal antibody technology to provide unprecedented therapeutic options for pets.



OUR STORY
PetMedix leverages an experienced scientific team and decades of human clinical research to develop fully species-specific, naturally generated therapeutic antibodies for pets. Here are some key moments in the company’s development and growth.
November 2017
Completion of PhD project adapting the transgenic platform from human to canine at Wellcome Sanger Institute
January 2018
Formation of PetMedix as a company
January 2019
Size of company: 12 staff
January 2020
Size of company: 24 staff
October 2020
Size of company: 32 staff
Welcome to PetMedix
Step into our research hub and meet some of our talented team
This footage was filmed in November 2020
Latest News
Twitter feed is not available at the moment.